CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma

2017
journal article
article
5
cris.lastimport.wos2024-04-09T21:55:49Z
dc.abstract.enIntroduction: Dendritic cells are crucial for cutaneous immune response. Their role in melanoma progression is however a matter of controversy. Material and methods: The number of dendritic cells within epidermis and in peri- and intratumoral location was analyzed using CD207 immunostain in 17 cases of in situ and 25 case of invasive melanoma. Results: Average peritumoral CD207+ cells count was 22.88 for all cases, 17.94 for in situ lesions and 26.24 for invasive cases. Average epidermal CD207+ cells count was 164.47 for all cases, 183.00 for in situ lesions and 150.78 - for invasive cases. In case of invasive melanomas, peritumoral CD207+ cells count was positively correlated with Breslow stage (R = 0.59) mitotic activity within the tumor (R = 0.62). Invasive cases with regression showed higher intratumoral and epidermal CD207+ cells count than the ones without (275.00 vs. 95.32 and 173.20 vs. 148.35) but lower peritumoral CD207+ cells count (17.60 vs. 27.26). Invasive cases with ulceration showed higher intratumoral and peritumoral CD207+ cells count than the ones without ulceration (220.08 vs. 55.67 and 44.17 vs. 9.69). Conclusions: CD207+ cells play a role in both progression and regression of melanoma but their exact role needs further studies.pl
dc.affiliationWydział Lekarski : Zakład Patomorfologii Klinicznej i Doświadczalnejpl
dc.affiliationWydział Lekarski : Klinika Pulmonologiipl
dc.cm.date2020-01-07
dc.cm.id83309
dc.contributor.authorDyduch, Grzegorz - 129300 pl
dc.contributor.authorTyrak, Katarzyna - 187123 pl
dc.contributor.authorGlajcar, Anna - 148470 pl
dc.contributor.authorSzpor, Joanna - 133600 pl
dc.contributor.authorOkoń, Krzysztof - 133027 pl
dc.date.accessioned2020-01-17T09:16:36Z
dc.date.available2020-01-17T09:16:36Z
dc.date.issued2017pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.number3pl
dc.description.physical233-239pl
dc.description.points15pl
dc.description.versionostateczna wersja wydawcy
dc.description.volume34pl
dc.identifier.doi10.5114/ada.2017.67845pl
dc.identifier.eissn2299-0046pl
dc.identifier.issn1642-395Xpl
dc.identifier.projectROD UJ / OPpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/140824
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa*
dc.rights.licenceCC-BY-NC-SA
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.pl*
dc.share.typeotwarte czasopismo
dc.subject.enmalignant melanomapl
dc.subject.endendritic cellspl
dc.subtypeArticlepl
dc.titleCD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanomapl
dc.title.journalPostępy Dermatologii i Alergologiipl
dc.typeJournalArticlepl
dspace.entity.typePublication
cris.lastimport.wos
2024-04-09T21:55:49Z
dc.abstract.enpl
Introduction: Dendritic cells are crucial for cutaneous immune response. Their role in melanoma progression is however a matter of controversy. Material and methods: The number of dendritic cells within epidermis and in peri- and intratumoral location was analyzed using CD207 immunostain in 17 cases of in situ and 25 case of invasive melanoma. Results: Average peritumoral CD207+ cells count was 22.88 for all cases, 17.94 for in situ lesions and 26.24 for invasive cases. Average epidermal CD207+ cells count was 164.47 for all cases, 183.00 for in situ lesions and 150.78 - for invasive cases. In case of invasive melanomas, peritumoral CD207+ cells count was positively correlated with Breslow stage (R = 0.59) mitotic activity within the tumor (R = 0.62). Invasive cases with regression showed higher intratumoral and epidermal CD207+ cells count than the ones without (275.00 vs. 95.32 and 173.20 vs. 148.35) but lower peritumoral CD207+ cells count (17.60 vs. 27.26). Invasive cases with ulceration showed higher intratumoral and peritumoral CD207+ cells count than the ones without ulceration (220.08 vs. 55.67 and 44.17 vs. 9.69). Conclusions: CD207+ cells play a role in both progression and regression of melanoma but their exact role needs further studies.
dc.affiliationpl
Wydział Lekarski : Zakład Patomorfologii Klinicznej i Doświadczalnej
dc.affiliationpl
Wydział Lekarski : Klinika Pulmonologii
dc.cm.date
2020-01-07
dc.cm.id
83309
dc.contributor.authorpl
Dyduch, Grzegorz - 129300
dc.contributor.authorpl
Tyrak, Katarzyna - 187123
dc.contributor.authorpl
Glajcar, Anna - 148470
dc.contributor.authorpl
Szpor, Joanna - 133600
dc.contributor.authorpl
Okoń, Krzysztof - 133027
dc.date.accessioned
2020-01-17T09:16:36Z
dc.date.available
2020-01-17T09:16:36Z
dc.date.issuedpl
2017
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.numberpl
3
dc.description.physicalpl
233-239
dc.description.pointspl
15
dc.description.version
ostateczna wersja wydawcy
dc.description.volumepl
34
dc.identifier.doipl
10.5114/ada.2017.67845
dc.identifier.eissnpl
2299-0046
dc.identifier.issnpl
1642-395X
dc.identifier.projectpl
ROD UJ / OP
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/140824
dc.languagepl
eng
dc.language.containerpl
eng
dc.rights*
Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa
dc.rights.licence
CC-BY-NC-SA
dc.rights.uri*
http://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.pl
dc.share.type
otwarte czasopismo
dc.subject.enpl
malignant melanoma
dc.subject.enpl
dendritic cells
dc.subtypepl
Article
dc.titlepl
CD207+/langerin positive dendritic cells in invasive and in situ cutaneous malignant melanoma
dc.title.journalpl
Postępy Dermatologii i Alergologii
dc.typepl
JournalArticle
dspace.entity.type
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
15
Views per month
Views per city
Ashburn
5
Krakow
2
Wroclaw
2
Chandler
1
Des Moines
1
Dublin
1
Downloads
dyduch_et-al_situ_cutaneous_malignant_melanoma_2017.pdf
10
dyduch_et-al_situ_cutaneous_malignant_melanoma_2017.odt
3